Status:
ACTIVE_NOT_RECRUITING
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Lead Sponsor:
Amgen
Collaborating Sponsors:
Colorado Prevention Center
Conditions:
Cardiovascular Disease
Myocardial Infarction
Eligibility:
All Genders
18-99 years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute s...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years
- Hospitalized for primary reason of NSTEMI or STEMI due to presumed atherosclerotic disease
Exclusion
- Participants requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening
- Participants with elevated biomarkers of myocardial injury due to secondary/nonatherosclerotic etiology (eg, sepsis, atrial fibrillation, vasospasm, decompensated heart failure, uncontrolled hypertension, stress induced cardiomyopathy)
Key Trial Info
Start Date :
October 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 29 2027
Estimated Enrollment :
6019 Patients enrolled
Trial Details
Trial ID
NCT05284747
Start Date
October 26 2022
End Date
May 29 2027
Last Update
October 6 2025
Active Locations (120)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Eastern Shore Research Institute
Fairhope, Alabama, United States, 36532
3
Heart Center Research LLC
Huntsville, Alabama, United States, 35801-4317
4
Northern Arizona Healthcare Corporation Cardiovascular Institute
Flagstaff, Arizona, United States, 86001